CClinicalTrials.gg
CompletedNCT00671502Updated Nov 9, 2011Results posted

A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back

A Phase 3 interventional study of Carisoprodol SR and Carisoprodol SR in Lower Back Pain, sponsored by Meda Pharmaceuticals. Completed at 68 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-11-09.

Sponsored by Meda Pharmaceuticals · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
840
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to determine if two sustained released formulations of carisoprodol are more effective than placebo.

Read the detailed description

Methodology:

This was a randomized, double-blind, double-dummy, placebo-controlled, parallel-group study in subjects 18-70 years of age with acute, painful, muscle spasm of the lower back. The study consisted of a baseline screening (Study Day 1), during which subjects were evaluated for inclusion/exclusion criteria, and a 7-day double-blind treatment period (Study Day 1 through Study Day 7). Subjects were randomly assigned to be dosed twice daily with one of the following double-blind treatments: sustained release(SR) carisoprodol 500-mg tablets,sustained release (SR) carisoprodol 700-mg tablets, or placebo.

Subjects were evaluated in the clinic on Study Days 1, 3 and 7. Subjects who remained symptomatic on Study Day 7 were allowed to continue in the study for a 7-day, double-blind extension period at the discretion of the Investigator. Subjects were contacted by telephone for a safety follow-up 7 days after the last dose of study medication.

A pharmacokinetic (PK) substudy was conducted at selected sites. These sites obtained blood samples for PK analysis at the end of the 7-day treatment period and the 14-day treatment period, if applicable.

02

Conditions studied

  • Lower Back Pain

Browse trials for

03

In context

Low Back Pain

2,818 studies on the registry are indexed under Low Back Pain; 482 are open to participants now.

This study's enrollment of 840 is above the median of 60 across 2,268 interventional studies indexed under Low Back Pain.

Browse Low Back Pain studies →

Lead sponsor

Meda Pharmaceuticals is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Onset of pain is within 3 days of first visit
  • Subject rating of pain must be 40 mm or greater on visual analog scale( VAS)
  • Ability to discontinue all analgesics, non steroidal anti inflammatory drug (NSAIDs), and other muscle relaxants
  • Willingness to provide written informed consent
  • Must be in generally good health

Exclusion criteria

Exclusion Criteria:

  • Presence of sciatic pain
  • History of clinically significant spine pathology such as herniated nucleas pulposis, spondylolisthesis, spinal stenosis
  • Presence of underlying chronic back pain
  • Neurological signs and symptoms such as numbness, tingling, foot drop, parethesia, unexplained constipation, urinary retention or urinary incontinence
  • Myocardial infaction within one year of study
  • Cancer not in remission or in remission less than one year
  • HIV or other immunodeficiency syndromes
  • History of osteoporosis or at high risk for vetebral fracture
  • Underlying rheumatologic disease such as rheumatoid arthritis, ankylosing spondylitis, etc.
  • Presence of active influenze or other viral syndromes
  • Morbid obesity basal metabolic index(BMI >39)
  • Evidence of infection, such as low grade fever or neutrophilia
  • Existence of any medical/surgical condition that could interfere with the evaluation of the study medication
  • Known history of alcohol or drug abuse
  • Injury involving high potential for litigation, including worker's compensation or automobile accidents
  • Pregnancy or breast feeding
  • Women of child-bearing potential not abstinent or not practicing a medically acceptable method of contraception
  • Vertebral body or spinous process, percussive tenderness on physical exam
  • Any abnormalities in the following tests of both lower extremities: ankle dorsiflexion strength, great toe dorsiflexion strength, absent or hypereflexic Achilles or patellar tendor reflexes, abnormal sensory exam in the medial, dorsal or lateral aspect of the foot and positive straight leg raise test
  • Urgent medical conditions on comprehensive exam that might indicate a more serious condition should be treated urgently
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
840 participants (actual)

Study arms

  • Experimental
    Carisoprodol 700mg

    tablet sustained release (SR)

    Drug: Carisoprodol SR

  • Experimental
    Carisoprodol 500mg

    sustained release(SR) tablet

    Drug: Carisoprodol SR

  • Placebo comparator
    Placebo

    tablet

    Drug: Placebo

Interventions

  • DrugCarisoprodol SR

    700 mg twice daily

    Also known as: sustained release(SR)

  • DrugCarisoprodol SR

    500 mg twice daily

    Also known as: sustained release(SR) tablet

  • DrugPlacebo

    Placebo tablet

    Also known as: no other name

06

What researchers measure

Primary outcomes

  1. Subject Rating of Pain on a 100-point Visual Analog Scale (VAS)

    the scale used was from 0 to 100 mm. 0 equaled no pain and 100 equaled maximum pain.participants measure their pain before treatment and during treatment at each visit

    Time frame: up to 14 days

Secondary outcomes

  1. Subject Functional Assessment Based on the Roland-Morris Disability Questionnaire (RMDQ)

    Time frame: up to 14 days

  2. Adverse Event Assessment

    the number of adverse events reported during the course of the study as reported by the participants

    Time frame: up to 21 days

07

Results

Posted Nov 9, 2011

Participant flow

Participant flow — Overall Study
MilestoneCarisoprodol 700mgCarisoprodol 500mg TabletPlacebo Tablet
Started281280279
Completed242241252
Not completed393927

Outcome measures

PrimarySubject Rating of Pain on a 100-point Visual Analog Scale (VAS)

the scale used was from 0 to 100 mm. 0 equaled no pain and 100 equaled maximum pain.participants measure their pain before treatment and during treatment at each visit

Time frame:
up to 14 days
Reported as:
Least squares mean · mm
Subject Rating of Pain on a 100-point Visual Analog Scale (VAS)
mmCarisoprodol 500mg TabletsCarisoprodol 700mg TabletsPlacebo Tablets
Subject Rating of Pain on a 100-point Visual Analog Scale (VAS)27.5 (-21 to 83)28 (-19 to 89)28.6 (-36 to 82)
SecondarySubject Functional Assessment Based on the Roland-Morris Disability Questionnaire (RMDQ)
Time frame:
up to 14 days

Results for this outcome have not been posted.

SecondaryAdverse Event Assessment

the number of adverse events reported during the course of the study as reported by the participants

Time frame:
up to 21 days
Reported as:
Number · participants

Results for this outcome have not been posted.

Adverse events

Collected over up to 21 days. Non-serious events are listed at a 0.7% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carisoprodol 700mg—0/278 (0%)78/278 (28.1%)
Carisoprodol 500mg Tablet—1/280 (0.4%)65/280 (23.2%)
Placebo Tablet—0/275 (0%)37/275 (13.5%)
Most frequent serious events
Most frequent serious events
EventCarisoprodol 700mgCarisoprodol 500mg TabletPlacebo Tablet
transient ischemic attackCardiac disorders0/2781/2800/275
Most frequent other events
Most frequent other events
EventCarisoprodol 700mgCarisoprodol 500mg TabletPlacebo Tablet
somnolenceNervous system disorders44/4436/28018/275
dizzinessNervous system disorders23/27812/2806/275
nauseaGastrointestinal disorders5/27812/2806/275
headacheGeneral disorders8/2784/2805/275
fatigueGeneral disorders5/2785/2802/275

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Carisoprodol 700mgCarisoprodol 500mg TabletPlacebo TabletTotal
<=18 years0000
Between 18 and 65 years278278275831
>=65 years3249
Age Continuous
Age Continuous(years)Carisoprodol 700mgCarisoprodol 500mg TabletPlacebo TabletTotal
Mean40.3 ± 13.0541.4 ± 12.640.9 ± 12.7240.9 ± 12.78
Sex: Female, Male
Sex: Female, Male(Participants)Carisoprodol 700mgCarisoprodol 500mg TabletPlacebo TabletTotal
Female133144136413
Male148136143427
Region of Enrollment
Region of Enrollment(participants)Carisoprodol 700mgCarisoprodol 500mg TabletPlacebo TabletTotal
United States281280279840
08

Study locations

68 sites
  • MedSearch, LLC
    Birmingham, Alabama 35235, United States
  • Genesis Clinical Research Corporation
    Huntsville, Alabama 35802, United States
  • Vaughn H. Mancha, Jr., PC Family Practice
    Montgomery, Alabama 36117, United States
  • Anasazi Internal Medicine PC
    Phoenix, Arizona 85032, United States
  • Heritage Physician Group
    Hot Springs, Arkansas 71913, United States
  • OrthoArkansas
    Little Rock, Arkansas 72205, United States
  • Family Practice Clinic
    North Little Rock, Arkansas 72114, United States
  • Quality of Life Medical Center, LLC
    Hawaiian Gardens, California 90716, United States
  • Trinity Health and Wellness
    Roseville, California 95661, United States
  • San Diego Sports Medicine & Family Health Center
    San Diego, California 92120, United States
  • Quality Care Medical Center, Inc.
    Vista, California 92084, United States
  • Anthony Roselli, MD
    Avon, Connecticut 06001, United States
  • Clinical Research of South Florida
    Coral Gables, Florida 33134, United States
  • Southeastern Integrated Medical, PL dba Florida Medical Research Institute
    Gainesville, Florida 32607, United States
  • South Florida Clinical Research Center
    Hollywood, Florida 33023, United States
  • FPA Clinical Research
    Kissimmee, Florida 34741, United States
  • Genesis Research International
    Longwood, Florida 32779, United States
  • Well Pharma Medical Research Corporation
    Miami, Florida 33143, United States
  • International Research Associates, LLC
    Miami, Florida 33156, United States
  • Tukoi Clinical Research
    Miami, Florida 33180, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • University Clinical Research, Inc.
    Pembroke Pines, Florida 33024, United States
  • Sunrise Medical Research #501
    Plantation, Florida 33324, United States
  • Southwest Florida Clinical Research Center
    Tampa, Florida 33609, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Perimeter Institute for Clinical Research, Inc.
    Atlanta, Georgia 30338, United States
  • Sunset Medical Research
    Sunset, Louisiana 70584, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01610, United States
  • Northern Pines Health Center
    Buckley, Michigan 49620, United States
  • KMED Research
    Clair Shores, Michigan 48081, United States
  • Harris & Associates, P.C.
    Detroit, Michigan 48235, United States
  • Valley Medical Center
    Flint, Michigan 48507, United States
  • Westside Family Medical Center, P.C.
    Kalamazoo, Michigan 49009, United States
  • Kansas City University of Medicine and BioSciences Dybedal Building
    Kansas City, Missouri 64106, United States
  • Comprehensive Clinical Research
    Berlin, New Jersey 08009, United States
  • South Jersey Medical Associations, PA
    Blackwood, New Jersey 08012, United States
  • Care Center of Family Practice & Pediatrics of Hamilton
    Hamilton, New Jersey 08610, United States
  • Partners in Primary Care
    Voorhees, New Jersey 08043, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Metrolina Medical Research
    Charlotte, North Carolina 28209, United States
  • Clinical Research Source Inc.
    Perrysburg, Ohio 43551, United States
  • Family Practice Center of Wadsworth, Inc.
    Wadsworth, Ohio 44281, United States
  • Integrated Medical Research
    Ashland, Oregon 97520, United States
  • Williamette Valley Clinical Studies
    Eugene, Oregon 91404, United States
  • Fanno Creek Clinic, LLC
    Portland, Oregon 97219, United States
  • Best Clinical Research - PA
    Philadelphia, Pennsylvania 19104, United States
  • Arcuri Clinical Research
    Philadelphia, Pennsylvania 19142, United States
  • Partners in Clinical Research
    Cumberland, Rhode Island 02864, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Robert S. Eagerton Jr., MD Family Practice
    Manning, South Carolina 29102, United States
  • Holston Medical Group, P.C.
    Bristol, Tennessee 37620, United States
  • ACRC Trials
    Addison, Texas 75001, United States
  • Arlington Family Health Pavilion
    Arlington, Texas 76012, United States
  • Central TX Clinical Research
    Austin, Texas 78705, United States
  • Mid-Cities Family Care
    Bedford, Texas 76021, United States
  • Evergreen Clinical Research, LLC
    Bellaire, Texas 77401, United States
  • Deer Park Family Clinic, P.A.
    Deer Park, Texas 77536, United States
  • Prime Care Medical Group
    Houston, Texas 77024, United States
  • West Houston Clinical Research
    Houston, Texas 77055, United States
  • North Hills Family Practice
    North Richland Hills, Texas 76180, United States
  • North Texas Family Medicine
    Plano, Texas 75093, United States
  • Sun Research Institute
    San Antonio, Texas 78205, United States
  • Unlimited Research
    San Antonio, Texas 78217, United States
  • InVisions Consultants, LLC
    San Antonio, Texas 78218, United States
  • Oakwell Clinical Research
    San Antonio, Texas 78218, United States
  • Health Research of Hampton Roads, Inc.
    Newport News, Virginia 23606, United States
  • Medical Research Initiatives
    Richmond, Virginia 23230, United States
  • Liberty Research Center
    Tacoma, Washington 98405, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 9, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00671502
Lead sponsor
Meda Pharmaceuticals
Responsible party
Sponsor
First posted
May 5, 2008
Start date
Apr 2008
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Nov 9, 2011
Last update
Nov 9, 2011

Study contacts

Lewis M. Fredane, MD
study director · Meda Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion